Here we present detailed laboratory recommendations, developed as part of the European Treatment and Outcome Study for CML (EUTOS), to enable testing laboratories to score MR in a reproducible manner for CML patients expressing the most common BCR-ABL1 variants. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.